Market closed

Rocket Pharmaceuticals/$RCKT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Ticker

$RCKT
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cranbury, United States

Employees

268
Website
www.rocketpharma.com

RCKT Metrics

BasicAdvanced
$978M
-
-$2.75
1.09
-

$978M

1.09

$31.47

$10.28

1.5M

6.047

5.894

6.912

7.776

-145.40%

-34.48%

-59.27%

2.96

3.68

-4.974

-13.14%

-3.21%

What the Analysts think about RCKT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.

RCKT Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RCKT Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

RCKT News

AllArticlesVideos
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Investopedia·4 weeks ago
3 Small-Cap Stocks That Are Ready to Rocket Higher

3 Small-Cap Stocks That Are Ready to Rocket Higher

MarketBeat·2 months ago
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RCKT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Rocket Pharmaceuticals stock?

Rocket Pharmaceuticals (RCKT) has a market cap of $978M as of January 15, 2025.

What is the P/E ratio for Rocket Pharmaceuticals stock?

The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of January 15, 2025.

Does Rocket Pharmaceuticals stock pay dividends?

No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Rocket Pharmaceuticals dividend payment date?

Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.

What is the beta indicator for Rocket Pharmaceuticals?

Rocket Pharmaceuticals (RCKT) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.